Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Deloitte
Accenture
Chubb
Merck
Medtronic

Generated: September 23, 2019

DrugPatentWatch Database Preview

Details for Patent: RE46276

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: RE46276
Title:Triazolo(4,5-D)pyrimidine compounds
Abstract: Triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation. The compounds of the invention have the formula (I) as follows: ##STR00001## wherein R, X and R.sup.1 through R.sup.3 are as defined in the specification.
Inventor(s): Hardem; David (Sutton Bonington, GB), Ingall; Anthony (Minehead, GB), Springthorpe; Brian (Stanford on Soar, GB), Willis; Paul (Geneva, CH), Guile; Simon (Hathern, GB)
Assignee: AstraZeneca UK Limited (London, GB)
Application Number:14/976,977
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent RE46276
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Process; Dosage form;

Drugs Protected by US Patent RE46276

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca Pharms BRILINTA ticagrelor TABLET;ORAL 022433-002 Sep 3, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y Y REDUCTION OF THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION ➤ Sign Up
Astrazeneca Pharms BRILINTA ticagrelor TABLET;ORAL 022433-002 Sep 3, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION ➤ Sign Up
Astrazeneca Pharms BRILINTA ticagrelor TABLET;ORAL 022433-002 Sep 3, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF MYOCARDIAL INFARCTION IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION ➤ Sign Up
Astrazeneca Pharms BRILINTA ticagrelor TABLET;ORAL 022433-002 Sep 3, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION ➤ Sign Up
Astrazeneca Pharms BRILINTA ticagrelor TABLET;ORAL 022433-001 Jul 20, 2011 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION ➤ Sign Up
Astrazeneca Pharms BRILINTA ticagrelor TABLET;ORAL 022433-001 Jul 20, 2011 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y REDUCTION OF THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: RE46276

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9804211Dec 4, 1998
Sweden9901271Apr 9, 1999
PCT Information
PCT FiledDecember 02, 1999PCT Application Number:PCT/SE99/02256
PCT Publication Date:June 15, 2000PCT Publication Number: WO00/34283

International Family Members for US Patent RE46276

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 023920 ➤ Sign Up
Argentina 058967 ➤ Sign Up
Argentina 072756 ➤ Sign Up
Austria 261970 ➤ Sign Up
Austria 418547 ➤ Sign Up
Austria 513816 ➤ Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
McKesson
Boehringer Ingelheim
Argus Health
Harvard Business School
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.